1Dunst J,Reese T,Sutter T,et al. Phase Ⅰ trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer [J]. J Clin Oncol,2002,20(19):3983- 3991.
2C.Andrew van Hasselt(尹怀信). Alan G Glibb(叶伟霖).NASOPHARYNGEAL CARCINOMA(中文版 )[M].北京:中国协和医科大学出版社,1999.217-225.
3Pignon JP,Bourhis J,Domenge C,et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer [J]. Lancet,2000,355(9208):949- 955.
4Miwa M,Ura M,Nishida M,et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue [J]. Eur J Cancer, 1998,34(8):1274- 1281.
5Sawada N,Ishikawa T,Sekiguchi F,et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine(Xeloda) in human cancer xenografts [J].Clin Cancer Res,1999,5(10):2948- 2953.
6Venturini M. Rational development of capecitabine [J]. Eur J Cancer,2002,2:3- 9.
7Cassidy J. Potential of Xeloda in colorectal cancer and other solid tumors [J]. Oncology, 1999, 57(1):27- 32.
8Andrew Sykesb,Nick Slevin,A phase Ⅰ study to determine the maximum tolerated dose(MTD) of capecitabine when given concurrently with radiotherapy in the treatment of squamous cell carcinoma of the head and neck [R]. Abstract 936 ASCO 2002.
9Hunt KK, Vorburger SA. Hurdles and Hopes for Cancer Treatment. Science, 2002, 19: 415-416.
10Frank DK. Gene Therapy for Head and Neck Cancer. Surg Oncol Clin N Am, 2002, 110: 708-726.
8Tang PA,Tsao MS,Moore MJ.A review of erlotinib and its clinical use[J].Expert O pin Phamacother,2006,7(2):177-193.
9Ang KK,Berkey BA,Tu X,et al.Impact of epidermal growth factor receptor expression on survival and patten of relapse in patients with advanced hesd and neck carcinoma[J].Cancer Res,2002,62(24):7350-7356.
10Soulieres D,Senzer NN,Vokes EE,et al.Multicenter phase Ⅱ study of erlotinib,an oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck[J].J Clin Oncol,2004,22:77.
